|
|
Post by centralcoastinvestor on Apr 24, 2018 15:04:28 GMT -5
I have been doing a lot of thinking about Mike Castagna’s comment about the hiring of David Kendall. Mike said something to the affect that David Kendall was the final piece to the leadership puzzle at MannKind. What does David bring to the table that MannKind did not have before? I went back and read through the 4th Quarter Earnings Call Transcript to see if I could develop an answer to that question. First, why would David Kendall come to MannKind in the first place. David must have had the knowledge that many consider MannKind a dying company. At the 4th Quarter Earnings Call, Mr. Kendall talked about the fact that he has 35 years of diabetes and diabetes research experience including working at Eli Lilly, Amylin, the ADA and diabetes research at the University of Minnesota (We won’t hold being affiliated with anything Minnesota against him. We can just overlook that one flaw.  ). I doubt that David needs the money and certainly doesn’t need the headache of coming to a failing company. So he came to MannKind for something more than money or additional experience after such an illustrious career. In his comments during the earnings call, Mr. Kendall said that Afrezza was a very unique asset. (I sure like the sound of that.) He went on to say that his new responsibilities include organizing and executing a well coordinated plan that covers research, clinical development, medical patient safety and regulatory activities. However, what I find most intriguing is Mr. Kendall’s reaction to the more than 60 studies that have been completed for Afrezza. He was very excited and surprised that so many studies have been done. Some may argue that MannKind had these studies for years and it didn’t do any good. However, when you bring someone in that has the vast experience in diabetes that Mr. Kendall has, he can see treasure where others only see junk and old news. In the Earnings Call, David mentioned that he was putting together a comprehensive Scientific Disclosure Plan based on the existing data. That’s the first time I have ever heard anyone in MannKind talk about a plan to consistently release information from all of the studies we have. MannKind and Afrezza have many impediments that are stacked against us. And we all argue about which one is the worst. I think its the combination of them that is so daunting. They include the following: Entrenched thinking of doctors and patients Hostile Insurance Environment Lack of funding resources Lack of Advertising Intense Competition Less than ideal FDA labeling - Need Ultra Fast Acting What MannKind is attempting to do is daunting and scary. And yet, David Kendall said yes to join that fight. So when one looks at the experience and connections that David Kendall brings to the table along with his interest in the new STAT study and the more the 60 completed studies to date on Afrezza, here is the David Kendall Effect that I foresee coming beginning with the release of the STAT studies at the ADA in June: 1. David will begin a sustained campaign of publishing both new and past test results to maintain a constant presence in the medical journal world. I believe Mr. Kendall has stated that if you are not publishing in medical journals and publications you are not staying relevant in the medical world. To cause a paradigm shift, the word on Afrezza must be continuously pushed to the front. 2. David will utilize his connections in the ADA and research arena to further push the idea that a paradigm shift is desperately needed in the treatment of meal time diabetic treatment. The STAT study will show proof of what can be done with a CGM and Afrezza. “Living Life Between the Lines.” 3. David will repackage past studies that have already been completed to seek further improvements to the Afrezza label with the FDA. I am ready for the David Kendall Effect to begin. It is why I think Mike Castagna is so excited to have him on board. |
|
|
|
Post by babaoriley on Apr 24, 2018 15:08:23 GMT -5
"Oh, one thing I was meaning to ask before I joined, Mike. I guess it slipped my mind - Afrezza is fully covered by most insurance companies, right?" |
|
|
|
Post by gamblerjag on Apr 24, 2018 15:10:31 GMT -5
I have been doing a lot of thinking about Mike Castagna’s comment about the hiring of David Kendall. Mike said something to the affect that David Kendall was the final piece to the leadership puzzle at MannKind. What does David bring to the table that MannKind did not have before? I went back and read through the 4th Quarter Earnings Call Transcript to see if I could develop an answer to that question. First, why would David Kendall come to MannKind in the first place. David must have had the knowledge that many consider MannKind a dying company. At the 4th Quarter Earnings Call, Mr. Kendall talked about the fact that he has 35 years of diabetes and diabetes research experience including working at Eli Lilly, Amylin, the ADA and diabetes research at the University of Minnesota (We won’t hold being affiliated with anything Minnesota against him. We can just overlook that one flaw. ). I doubt that David needs the money and certainly doesn’t need the headache of coming to a failing company. So he came to MannKind for something more than money or additional experience after such an illustrious career. In his comments during the earnings call, Mr. Kendall said that Afrezza was a very unique asset. (I sure like the sound of that.) He went on to say that his new responsibilities include organizing and executing a well coordinated plan that covers research, clinical development, medical patient safety and regulatory activities. However, what I find most intriguing is Mr. Kendall’s reaction to the more than 60 studies that have been completed for Afrezza. He was very excited and surprised that so many studies have been done. Some may argue that MannKind had these studies for years and it didn’t do any good. However, when you bring someone in that has the vast experience in diabetes that Mr. Kendall has, he can see treasure where others only see junk and old news. In the Earnings Call, David mentioned that he was putting together a comprehensive Scientific Disclosure Plan based on the existing data. That’s the first time I have ever heard anyone in MannKind talk about a plan to consistently release information from all of the studies we have. MannKind and Afrezza have many impediments that are stacked against us. And we all argue about which one is the worst. I think its the combination of them that is so daunting. They include the following: Entrenched thinking of doctors and patients Hostile Insurance Environment Lack of funding resources Lack of Advertising Intense Competition Less than ideal FDA labeling - Need Ultra Fast Acting What MannKind is attempting to do is daunting and scary. And yet, David Kendall said yes to join that fight. So when one looks at the experience and connections that David Kendall brings to the table along with his interest in the new STAT study and the more the 60 completed studies to date on Afrezza, here is the David Kendall Effect that I foresee coming beginning with the release of the STAT studies at the ADA in June: 1. David will begin a sustained campaign of publishing both new and past test results to maintain a constant presence in the medical journal world. I believe Mr. Kendall has stated that if you are not publishing in medical journals and publications you are not staying relevant in the medical world. To cause a paradigm shift, the word on Afrezza must be continuously pushed to the front. 2. David will utilize his connections in the ADA and research arena to further push the idea that a paradigm shift is desperately needed in the treatment of meal time diabetic treatment. The STAT study will show proof of what can be done with a CGM and Afrezza. “Living Life Between the Lines.” 3. David will repackage past studies that have already been completed to seek further improvements to the Afrezza label with the FDA. I am ready for the David Kendall Effect to begin. It is why I think Mike Castagna is so excited to have him on board. boy I hate to read but I enjoyed that novel thanks central |
|
|
|
Post by centralcoastinvestor on Apr 24, 2018 15:13:07 GMT -5
I have been doing a lot of thinking about Mike Castagna’s comment about the hiring of David Kendall. Mike said something to the affect that David Kendall was the final piece to the leadership puzzle at MannKind. What does David bring to the table that MannKind did not have before? I went back and read through the 4th Quarter Earnings Call Transcript to see if I could develop an answer to that question. First, why would David Kendall come to MannKind in the first place. David must have had the knowledge that many consider MannKind a dying company. At the 4th Quarter Earnings Call, Mr. Kendall talked about the fact that he has 35 years of diabetes and diabetes research experience including working at Eli Lilly, Amylin, the ADA and diabetes research at the University of Minnesota (We won’t hold being affiliated with anything Minnesota against him. We can just overlook that one flaw. ). I doubt that David needs the money and certainly doesn’t need the headache of coming to a failing company. So he came to MannKind for something more than money or additional experience after such an illustrious career. In his comments during the earnings call, Mr. Kendall said that Afrezza was a very unique asset. (I sure like the sound of that.) He went on to say that his new responsibilities include organizing and executing a well coordinated plan that covers research, clinical development, medical patient safety and regulatory activities. However, what I find most intriguing is Mr. Kendall’s reaction to the more than 60 studies that have been completed for Afrezza. He was very excited and surprised that so many studies have been done. Some may argue that MannKind had these studies for years and it didn’t do any good. However, when you bring someone in that has the vast experience in diabetes that Mr. Kendall has, he can see treasure where others only see junk and old news. In the Earnings Call, David mentioned that he was putting together a comprehensive Scientific Disclosure Plan based on the existing data. That’s the first time I have ever heard anyone in MannKind talk about a plan to consistently release information from all of the studies we have. MannKind and Afrezza have many impediments that are stacked against us. And we all argue about which one is the worst. I think its the combination of them that is so daunting. They include the following: Entrenched thinking of doctors and patients Hostile Insurance Environment Lack of funding resources Lack of Advertising Intense Competition Less than ideal FDA labeling - Need Ultra Fast Acting What MannKind is attempting to do is daunting and scary. And yet, David Kendall said yes to join that fight. So when one looks at the experience and connections that David Kendall brings to the table along with his interest in the new STAT study and the more the 60 completed studies to date on Afrezza, here is the David Kendall Effect that I foresee coming beginning with the release of the STAT studies at the ADA in June: 1. David will begin a sustained campaign of publishing both new and past test results to maintain a constant presence in the medical journal world. I believe Mr. Kendall has stated that if you are not publishing in medical journals and publications you are not staying relevant in the medical world. To cause a paradigm shift, the word on Afrezza must be continuously pushed to the front. 2. David will utilize his connections in the ADA and research arena to further push the idea that a paradigm shift is desperately needed in the treatment of meal time diabetic treatment. The STAT study will show proof of what can be done with a CGM and Afrezza. “Living Life Between the Lines.” 3. David will repackage past studies that have already been completed to seek further improvements to the Afrezza label with the FDA. I am ready for the David Kendall Effect to begin. It is why I think Mike Castagna is so excited to have him on board. boy I hate to read but I enjoyed that novel thanks central The funny thing is that I’m not the best writer. It takes me a long time to write something. But it was important to try and convey what a great asset David Kendall will be to our company. |
|
|
|
Post by lennymnkd on Apr 24, 2018 15:20:00 GMT -5
Loved it !
|
|
|
|
Post by myocat on Apr 24, 2018 15:21:14 GMT -5
centralcoastinvestor
Nice write up. For me, all I like to see is $ale, $ale and $sale.
|
|
|
|
Post by mnkdfann on Apr 24, 2018 15:31:12 GMT -5
Was this the elevator pitch for a documentary, or simply fan fiction? Time will tell.
|
|
|
|
Post by mnholdem on Apr 24, 2018 16:00:33 GMT -5
Perhaps that "final piece" is somebody who will educate the medical industry. I've received a number of emails from shareholders who have spoken to doctors who told them that they wanted to hold off prescribing Afrezza until more was known about it. Not "until it's popular" or "until there's better coverage" or "until they lower the price".
They want to know more. I think Dr. Kendall has exactly the right qualification to give physicians a LOT of information that the diabetes treatment industry will take seriously.
 |
|
|
|
Post by centralcoastinvestor on Apr 24, 2018 16:04:06 GMT -5
Perhaps that "final piece" is somebody who will educate the medical industry. I've received a number of emails from shareholders who have spoken to doctors who told them that they wanted to hold off prescribing Afrezza until more was known about it. Not "until it's popular" or "until there's better coverage" or "until they lower the price".
They want to know more. I think Dr. Kendall has exactly the right qualification to give physicians a LOT of information that the diabetes treatment industry will take seriously.
I was hoping you would comment on the Minnesota wisecrack I made in the post. Oh well. |
|
|
|
Post by celo on Apr 24, 2018 16:05:18 GMT -5
Based on Central coast's write up, the FDA changed their view on Afrezza. In minutes time...wow! I didn't know that's all it took. |
|
|
|
Post by boca1girl on Apr 24, 2018 16:06:44 GMT -5
I have been doing a lot of thinking about Mike Castagna’s comment about the hiring of David Kendall. Mike said something to the affect that David Kendall was the final piece to the leadership puzzle at MannKind. What does David bring to the table that MannKind did not have before? I went back and read through the 4th Quarter Earnings Call Transcript to see if I could develop an answer to that question. First, why would David Kendall come to MannKind in the first place. David must have had the knowledge that many consider MannKind a dying company. At the 4th Quarter Earnings Call, Mr. Kendall talked about the fact that he has 35 years of diabetes and diabetes research experience including working at Eli Lilly, Amylin, the ADA and diabetes research at the University of Minnesota (We won’t hold being affiliated with anything Minnesota against him. We can just overlook that one flaw. ). I doubt that David needs the money and certainly doesn’t need the headache of coming to a failing company. So he came to MannKind for something more than money or additional experience after such an illustrious career. In his comments during the earnings call, Mr. Kendall said that Afrezza was a very unique asset. (I sure like the sound of that.) He went on to say that his new responsibilities include organizing and executing a well coordinated plan that covers research, clinical development, medical patient safety and regulatory activities. However, what I find most intriguing is Mr. Kendall’s reaction to the more than 60 studies that have been completed for Afrezza. He was very excited and surprised that so many studies have been done. Some may argue that MannKind had these studies for years and it didn’t do any good. However, when you bring someone in that has the vast experience in diabetes that Mr. Kendall has, he can see treasure where others only see junk and old news. In the Earnings Call, David mentioned that he was putting together a comprehensive Scientific Disclosure Plan based on the existing data. That’s the first time I have ever heard anyone in MannKind talk about a plan to consistently release information from all of the studies we have. MannKind and Afrezza have many impediments that are stacked against us. And we all argue about which one is the worst. I think its the combination of them that is so daunting. They include the following: Entrenched thinking of doctors and patients Hostile Insurance Environment Lack of funding resources Lack of Advertising Intense Competition Less than ideal FDA labeling - Need Ultra Fast Acting What MannKind is attempting to do is daunting and scary. And yet, David Kendall said yes to join that fight. So when one looks at the experience and connections that David Kendall brings to the table along with his interest in the new STAT study and the more the 60 completed studies to date on Afrezza, here is the David Kendall Effect that I foresee coming beginning with the release of the STAT studies at the ADA in June: 1. David will begin a sustained campaign of publishing both new and past test results to maintain a constant presence in the medical journal world. I believe Mr. Kendall has stated that if you are not publishing in medical journals and publications you are not staying relevant in the medical world. To cause a paradigm shift, the word on Afrezza must be continuously pushed to the front. 2. David will utilize his connections in the ADA and research arena to further push the idea that a paradigm shift is desperately needed in the treatment of meal time diabetic treatment. The STAT study will show proof of what can be done with a CGM and Afrezza. “Living Life Between the Lines.” 3. David will repackage past studies that have already been completed to seek further improvements to the Afrezza label with the FDA. I am ready for the David Kendall Effect to begin. It is why I think Mike Castagna is so excited to have him on board. Nice review, but he has earned the title Dr. Just a typo, I know. |
|
|
|
Post by mnholdem on Apr 24, 2018 16:08:04 GMT -5
Perhaps that "final piece" is somebody who will educate the medical industry. I've received a number of emails from shareholders who have spoken to doctors who told them that they wanted to hold off prescribing Afrezza until more was known about it. Not "until it's popular" or "until there's better coverage" or "until they lower the price".
They want to know more. I think Dr. Kendall has exactly the right qualification to give physicians a LOT of information that the diabetes treatment industry will take seriously.
I was hoping you would comment on the Minnesota wisecrack I made in the post. Oh well. Take it from a fisherman, you need better bait to get me to bite. |
|
|
|
Post by centralcoastinvestor on Apr 24, 2018 16:24:56 GMT -5
I have been doing a lot of thinking about Mike Castagna’s comment about the hiring of David Kendall. Mike said something to the affect that David Kendall was the final piece to the leadership puzzle at MannKind. What does David bring to the table that MannKind did not have before? I went back and read through the 4th Quarter Earnings Call Transcript to see if I could develop an answer to that question. First, why would David Kendall come to MannKind in the first place. David must have had the knowledge that many consider MannKind a dying company. At the 4th Quarter Earnings Call, Mr. Kendall talked about the fact that he has 35 years of diabetes and diabetes research experience including working at Eli Lilly, Amylin, the ADA and diabetes research at the University of Minnesota (We won’t hold being affiliated with anything Minnesota against him. We can just overlook that one flaw. ). I doubt that David needs the money and certainly doesn’t need the headache of coming to a failing company. So he came to MannKind for something more than money or additional experience after such an illustrious career. In his comments during the earnings call, Mr. Kendall said that Afrezza was a very unique asset. (I sure like the sound of that.) He went on to say that his new responsibilities include organizing and executing a well coordinated plan that covers research, clinical development, medical patient safety and regulatory activities. However, what I find most intriguing is Mr. Kendall’s reaction to the more than 60 studies that have been completed for Afrezza. He was very excited and surprised that so many studies have been done. Some may argue that MannKind had these studies for years and it didn’t do any good. However, when you bring someone in that has the vast experience in diabetes that Mr. Kendall has, he can see treasure where others only see junk and old news. In the Earnings Call, David mentioned that he was putting together a comprehensive Scientific Disclosure Plan based on the existing data. That’s the first time I have ever heard anyone in MannKind talk about a plan to consistently release information from all of the studies we have. MannKind and Afrezza have many impediments that are stacked against us. And we all argue about which one is the worst. I think its the combination of them that is so daunting. They include the following: Entrenched thinking of doctors and patients Hostile Insurance Environment Lack of funding resources Lack of Advertising Intense Competition Less than ideal FDA labeling - Need Ultra Fast Acting What MannKind is attempting to do is daunting and scary. And yet, David Kendall said yes to join that fight. So when one looks at the experience and connections that David Kendall brings to the table along with his interest in the new STAT study and the more the 60 completed studies to date on Afrezza, here is the David Kendall Effect that I foresee coming beginning with the release of the STAT studies at the ADA in June: 1. David will begin a sustained campaign of publishing both new and past test results to maintain a constant presence in the medical journal world. I believe Mr. Kendall has stated that if you are not publishing in medical journals and publications you are not staying relevant in the medical world. To cause a paradigm shift, the word on Afrezza must be continuously pushed to the front. 2. David will utilize his connections in the ADA and research arena to further push the idea that a paradigm shift is desperately needed in the treatment of meal time diabetic treatment. The STAT study will show proof of what can be done with a CGM and Afrezza. “Living Life Between the Lines.” 3. David will repackage past studies that have already been completed to seek further improvements to the Afrezza label with the FDA. I am ready for the David Kendall Effect to begin. It is why I think Mike Castagna is so excited to have him on board. Nice review, but he has earned the title Dr. Just a typo, I know. Good catch. I will try and update the post with Dr. At this point, I’m having tough time finding the edit button that is normally available. Liane, I don’t seem to be able to edit my first post in this thread. I need to change Mr. to Dr. wherever it shows up. How do I do that? |
|
|
|
Post by mango on Apr 24, 2018 17:39:02 GMT -5
Great write up, thank you for this!
|
|
|
|
Post by hellodolly on Apr 24, 2018 17:55:57 GMT -5
I have been doing a lot of thinking about Mike Castagna’s comment about the hiring of David Kendall. Mike said something to the affect that David Kendall was the final piece to the leadership puzzle at MannKind. What does David bring to the table that MannKind did not have before? I went back and read through the 4th Quarter Earnings Call Transcript to see if I could develop an answer to that question. First, why would David Kendall come to MannKind in the first place. David must have had the knowledge that many consider MannKind a dying company. At the 4th Quarter Earnings Call, Mr. Kendall talked about the fact that he has 35 years of diabetes and diabetes research experience including working at Eli Lilly, Amylin, the ADA and diabetes research at the University of Minnesota (We won’t hold being affiliated with anything Minnesota against him. We can just overlook that one flaw. ). I doubt that David needs the money and certainly doesn’t need the headache of coming to a failing company. So he came to MannKind for something more than money or additional experience after such an illustrious career. In his comments during the earnings call, Mr. Kendall said that Afrezza was a very unique asset. (I sure like the sound of that.) He went on to say that his new responsibilities include organizing and executing a well coordinated plan that covers research, clinical development, medical patient safety and regulatory activities. However, what I find most intriguing is Mr. Kendall’s reaction to the more than 60 studies that have been completed for Afrezza. He was very excited and surprised that so many studies have been done. Some may argue that MannKind had these studies for years and it didn’t do any good. However, when you bring someone in that has the vast experience in diabetes that Mr. Kendall has, he can see treasure where others only see junk and old news. In the Earnings Call, David mentioned that he was putting together a comprehensive Scientific Disclosure Plan based on the existing data. That’s the first time I have ever heard anyone in MannKind talk about a plan to consistently release information from all of the studies we have. MannKind and Afrezza have many impediments that are stacked against us. And we all argue about which one is the worst. I think its the combination of them that is so daunting. They include the following: Entrenched thinking of doctors and patients Hostile Insurance Environment Lack of funding resources Lack of Advertising Intense Competition Less than ideal FDA labeling - Need Ultra Fast Acting What MannKind is attempting to do is daunting and scary. And yet, David Kendall said yes to join that fight. So when one looks at the experience and connections that David Kendall brings to the table along with his interest in the new STAT study and the more the 60 completed studies to date on Afrezza, here is the David Kendall Effect that I foresee coming beginning with the release of the STAT studies at the ADA in June: 1. David will begin a sustained campaign of publishing both new and past test results to maintain a constant presence in the medical journal world. I believe Mr. Kendall has stated that if you are not publishing in medical journals and publications you are not staying relevant in the medical world. To cause a paradigm shift, the word on Afrezza must be continuously pushed to the front. 2. David will utilize his connections in the ADA and research arena to further push the idea that a paradigm shift is desperately needed in the treatment of meal time diabetic treatment. The STAT study will show proof of what can be done with a CGM and Afrezza. “Living Life Between the Lines.” 3. David will repackage past studies that have already been completed to seek further improvements to the Afrezza label with the FDA. I am ready for the David Kendall Effect to begin. It is why I think Mike Castagna is so excited to have him on board. Thanks for the time and effort to put this together. I usually have no troubles writing but, it has to be in my wheel house and diabetes is definitely not in my wheel house. Then, I still do a lot of editing and rewrites...even in blogs. I think you hit on some very important points to consider...the first (for me) being that he left his position at Lily and came to MNKD to continue his passion for research, leadership and contributing to patient care. It's not the money. I think he sees a different direction in the diabetes care industry and he wants to make sure that he takes all of his institutional knowledge and apply it in order to ultimately push for a new agenda in diabetes SOC. Everything else just falls into place along the way. That institutional knowledge is what Mike paid for... |
|
). I doubt that David needs the money and certainly doesn’t need the headache of coming to a failing company. So he came to MannKind for something more than money or additional experience after such an illustrious career.
